REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction

ST-elevation Myocardial Infarction (STEMI) Clinical Trial

— REFLO-STEMI  

Official title:

Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01747174
• Other study ID #: CLRN 53469
• Secondary ID: 2010-023211-3409
• Status: Completed
• Phase: Phase 2
• First received: November 20, 2012
• Last updated: June 15, 2015
• Start date: October 2011
• Est. completion date: December 2014

Study information

• Verified date: June 2015
• Source: University Hospitals, Leicester
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Institute for Health Research
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether intra-coronary adenosine or sodium nitroprusside (SNP) delivered selectively via a thrombus aspiration catheter (or if unsuccessful via a coronary microcatheter) following thrombus aspiration in Primary Percutaneous Coronary Intervention (P-PCI) reduces microvascular obstruction (MVO) parameters and infarct size as measured with cardiac MRI, compared with standard treatment following thrombus aspiration in patients presenting with ST-elevation myocardial infarction (STEMI).

Description:

>100,000 patients suffering STEMI present in the UK each year. P-PCI in the UK is increasing exponentially. In 2004 there were <1500 P-PCI and in 2007 and 2008 these figures had increased to 5902 and 9224 respectively (BCIS database).

Although P-PCI delivered quickly is more effective than thrombolysis, the efficacy of this, essentially mechanical, technique is limited by the unpredictable phenomenon of no-reflow and the under-stated lesser degrees of MVO. As more UK centres adopt P-PCI the dilemma of how to attenuate MVO will remain. Currently there is no consensus on the optimal management to prevent or attenuate MVO particularly when thrombus laden lesions are treated with P-PCI.

There is divergent clinical practice, even within institutions, in the UK and worldwide. This is because there is no solid evidence base to inform clinicians. The current options for interventional cardiologists are:

1. Routinely aspirate thrombus and give IC vasodilator during the intervention but only in high burden thrombus formation lesions.

2. Perform a standard P-PCI only and then give IV vasodilator if angiographic no-reflow develops.

3. Routinely consider that angiographically silent MVO (i.e a grade below true "no-reflow") may have important impact on infarct size and clinical outcome and treat prophylactically.

Few if any clinicians follow this thinking. Indeed, it appears impossible to predict the incidence of (no-reflow/MVO) from the presenting angiogram (pre- or post- wire or balloon) and it can be argued that irrespective of thrombus burden it would be better to undertake prophylactic treatment in all patients, following the use of aspiration catheter, with delivery of agents able, in theory at least, to reduce (angiographically undetectable) MVO. Several studies of IC adenosine or SNP have shown favourable effects in attenuating MVO. However, the size of effect with either drug and whether indeed there is a difference between them in reducing MVO and infarct size is undetermined.

The objectives of our proposed study are to determine:

1. Whether adjunctive pharmaco-therapy at time of P-PCI and following thrombus aspiration, reduces CMR-determined MVO and infarct size.

2. Whether there is a difference between adenosine and SNP in reducing CMR-detected MVO and infarct size, both given selectively and distally via a thrombus aspiration catheter or a coronary microcatheter.

3. The correlation of angiographic, including the recently designed computer-assisted myocardial blush quantification 'Quantitative Blush Evaluator'(QuBE), and other myocardial perfusion markers, with CMR detected MVO and infarct size, as well as with clinical outcome (MACE) at 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 247
• Est. completion date: December 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years age.

• Informed ASSENT (verbal consent) prior to angiography.

• STEMI = 6 hrs of symptom onset, requiring primary reperfusion by PCI.

• Single-vessel coronary artery disease (non culprit disease =70% stenosis at angiography)

• TIMI flow 0/I at angiography.

Exclusion Criteria:

• Contraindications to: P-PCI *, CMR**, contrast agents, or study medications:

Adenosine***, SNP****, Aspirin, Thienopyridine and Bivalirudin.

• SBP = 90mmHg

• Cardiogenic Shock

• Previous Q wave myocardial infarction

• Culprit lesion not identified or located in a by-pass graft

• Stent thrombosis.

• Left main disease.

• Known severe asthma.

• Known stage 4 or 5 chronic kidney disease (eGFR<30ml/min).

• Pregnancy.

Notes:

• * Exclusion criteria for P-PCI (presentation timing, inadequate arterial access etc); patient unable to tolerate "prolonged" PCI procedure (in operators' opinion).

• ** Absolute contra-indication to CMR (Pacemaker, ICD, intra-cranial metal clips).

• *** Contraindications to Adenosine (known hypersensitivity to Adenosine, sick sinus syndrome, second or third degree atrio-ventricular block - except in patients with functioning artificial pacemaker, long QT syndrome has been defined as QTc > 450 ms at baseline). ECG will be undertaken just after the first dose of the study drug and QT/QTc will be recorded and compared to the baseline. If the QTc recorded after the first dose of the study drug exceeds 450ms or there is an increase in the QT/QTc of > 60 ms from baseline, the second dose will be abandoned and this will be recorded.

• **** Contraindications to SNP (known hypersensitivity to SNP, compensatory hypertension - as may be seen in arteriovenous shunts or coarctation of the aorta, high output failure, congenital optic atrophy or tobacco amblyopia).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• ST-elevation Myocardial Infarction (STEMI)

Intervention

Drug:
• IC Adenosine
IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
• IC Sodium nitroprusside (SNP)
IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.

Procedure:
• Standard PCI
PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.

Locations

Country	Name	City	State
United Kingdom	University Hospital	Coventry	West Midlands
United Kingdom	Leeds General Infirmary	Leeds	West Yorkshire
United Kingdom	Glenfield Hospital	Leicester	Leicestershire
United Kingdom	Freeman Hospital	Newcastle upon Tyne	Tyne and Wear

Sponsors (1)

Lead Sponsor	Collaborator
University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CMR measured infarct size (% LV mass)		48-72 hours post procedure	Yes
Secondary	CMR incidence and extent of MVO (% LV mass)		48-72 hours post procedure	Yes
Secondary	CMR measured myocardial salvage index, haemorrhage, LV EF and volumes		48-72 hours post procedure	Yes
Secondary	Myocardial Blush Grade assessed by validated computer software 'Quantitative Blush Evaluator' (QuBE		During P-PCI	No
Secondary	Incidence pre- and post- procedure angiographic true "no-reflow"		During P-PCI	No
Secondary	Any in-patient clinical events	Includes: coronary artery re-occlusion, need for repeat PCI, recurrent chest pain with new ECG changes, incidence of clinical heart failure (symptoms plus basal crackles plus X-ray evidence of pulmonary congestion) and proven cerebrovascular accident (CVA).	Within 6 months from presentation with, and PCI for, STEMI	Yes
Secondary	Overall MACE	MACE: composite of death, need for target lesion revascularization, recurrent MI, severe heart failure, and CVA.	1 month	Yes
Secondary	Degree of ST segment resolution on ECG		Assessed immediately following P-PCI (expected on average 1 hour)	No
Secondary	Echocardiographic assessment of LV	To include end systolic/diastolic volumes, EF +/- wall motion index	6-8 weeks post-procedure/MI	No
Secondary	Corrected TIMI Frame Count	TIMI frame count or TFC is defined as the number of cineframes required for contrast to reach a standardized distal coronary landmark in the culprit vessel.	During procedure	No